Featured Posts
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
Search Posts
Washington Examiner
The Biden administration shouldn’t waste more taxpayer dollars on COVID vaccines
A Food and Drug Administration advisory committee recently voted to recommend updating the COVID-19 vaccine. But important questions remain: When…
The Center Square
Fauci takes heat after casting doubt on efficacy of COVID vaccines
CEI’s Joel Zinberg is cited in The Center Square on COVID vaccines: Joel Zinberg, a Competitive Enterprise Institute senior fellow, blasted Fauci for pushing for…
Blog
New Inflation Numbers Show Folly of Price Controls
Today’s release of inflation numbers by the Bureau of Labor Statistics confirms that the loudest voices in favor of price controls are usually the…
Letters
CEI Joins Coalition Opposing March-In over Drug Prices
Dear Secretary Becerra, On behalf of millions of Americans across the country, we urge you to ignore calls and petitions asking you to deliberately twist…
Letters
CEI Joins Coalition Urging Congress to End Ban on DC Marijuana Sales
Dear Members of Congress, As you and your colleagues in Congress continue to finalize funding levels and bill language in the FY22 appropriations bill, the…
Letters
CEI Joins NTU-Led Coalition Warns of BBB’s Impact on Drug Competition
Dear Senators and Representatives: On behalf of the undersigned organizations — taxpayer, consumer, and free market advocates from across the country — we write with…